Evoq Remedies Ltd Financials
Company Logo

Evoq Remedies Ltd Financial Statement

Evoq Remedies Ltd Income Statement

Quarterly

Annual

*All values are in Rs. Cr

No Data Available

Invest in Evoq Remedies Ltd
₹0 Brokerage*
Open Demat Account
*By signing up you agree to our Terms and Conditions

Evoq Remedies Ltd Profit & Loss

*All values are in Rs. Cr

Standalone

Consolidated

Particulars
Mar 2024
Total Revenue Annual4.05
Operating Expenses Annual5.69
Operating Profit Annual0.62
Interest Annual0.00
Depreciation0.01
Net Profit Annual0.45
Tax Annual0.16

Evoq Remedies Ltd Cash Flow

*All values are in Rs. Cr

Standalone

Consolidated

Particulars
Mar 2024
Cash Flow at the Beginning0.15
Cash Flow from Operations5.32
Cash Flow from Investing-0.01
Cash Flow from Financing-5.34
Cash Flow at the End0.12

Evoq Remedies Ltd Key Ratios

*All values are in Rs. Cr

Standalone

Consolidated

Particulars
Mar 2024
PBDIT Margin (%)15.31
PBIT Margin (%)15.06
PBT Margin (%)15.06
Net PROFIT Margin (%)11.11
Return On Networth / Equity (%)1.80
Return On Networth /Employed (%)1.91
Return On Assets (%)1.44
Total Debt / Equity (X)0.28
Asset Turnover Ratio (%)0.13

Evoq Remedies Ltd Balance Sheet

*All values are in Rs. Cr

Standalone

Consolidated

Particulars
Mar 2024
Fixed Assets Annual0.01
Total Current Assets Annual36.85
Non Current Assets Annual0.01
Total Shareholders Funds Annual25.24
Total Assets Annual36.86

Evoq Remedies Ltd Earning Calls

No Data Availabe

Get Your FAQs Right

As of Nov 23, 2024, Evoq Remedies Ltd has a market capitalization of 11.79 Cr. Value Research classifies it as a Micro-Cap company.
Yes, Evoq Remedies Ltd is debt-free with a debt-to-equity ratio of 0.17.
In FY 2023 , Evoq Remedies Ltd recorded a total revenue of approximately 4.05 Cr marking a significant milestone in the company's financial performance.
Evoq Remedies Ltd's Future outlook anticipates robust growth, with forecasted earnings and revenue rising approximately -0.5% and -0.7% annually, respectively..
Evoq Remedies Ltd's current PE ratio is 26.20.
Evoq Remedies Ltd's ROCE averaged 4.5% from the FY ending March 2022 to 2024, with a median of 4.7%. It peaked at 6.6% in March 2023, reflecting strong capital efficiency over the period..
Evoq Remedies Ltd's latest EBIT is Rs. 0.61 Cr, surpassing the average EBIT of Rs. 1.45 Cr over the 5 years..